SIMPLE TO USE
BATTERY POWERED
NON-MYDRIATIC
AI READY*
Remidio Fundus On Phone is the world’s first and the only smartphone based, Infrared enabled, high quality disease detection and triaging device to enable universal screening for eye health.
Artificial intelligence can play a unique role in public health screening for detection of Diabetic Retinopathy. Remidio has clinically validated two different AI algorithms : EyeArt from EyeNuk, CA, USA and Medios Technologies from Singapore.
* EyeArt from EyeNuk has been cleared for sales as a Class II a medical device by EU and as a Class 2 medical device by Health Canada. In the US, EyeArt is limited by federal law to investigational use and is not available for sale.
The Fundus on Phone is extremely compact by design, with the width of the system measuring just 6.8cm and weight over 1.5kg. The design allows it to be used even in the most space-starved settings! It can be used in mass screening programs such as screening for Cataract, Glaucoma and Diabetic Retinopathy.
HANDHELD
SLIT LAMP MOUNTABLE
TABLE-MOUNTED
FOP is an ideal platform for comprehensive telemedicine enabled eye-wellness screening. The cloud synchronized mobile application of FOPNM-10 enables images to be synced and archived securely in the cloud for remote review and clinical management. Remidio Web Application allows the user to securely login and review images remotely across the globe.
# DICOM App not available for sale in the US
Remidio FOP is shown to have a clinical specificity of 98% for any DR against Zeiss FF450.
Remidio FOP Vs Zeiss FF450 | ||
Retinopathy | Sensitivity | Specificity |
Any DR | 92.7 | 98.4 |
DME | 89.8 | 98.4 |
PDR | 89.1 | 95.8 |
STDR | 86.6 | 94.6 |
RDR | 87.9 | 94.9 |
EyeArt Vs Ophthamologist | ||
Retinopathy | Sensitivity | Specificity |
Any DR | 95.8 | 80.2 |
DME | 97.0 | 75.2 |
PDR | 78.1 | 89.8 |
STDR | 99.1 | 80.4 |
RDR | 99.1 | 68.8 |
Published in Nature Eye.
Medios AI Vs Ophthalmologist | ||
Retinopathy | Sensitivity | Specificity |
Any DR | 85.2 | 92 |
RDR | 100 | 88.4 |
Under review for publication in JAMA Ophthalmology.